Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex®) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy

NCT02970747 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT02970747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02970747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex®) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy
Lead sponsor
iOMEDICO AG
Phase
Observational
Overall status
Completed
Start date
October 25, 2016
Completion date
April 26, 2025
Enrollment
359 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse